![]() |
|
|
Vol. 284, Issue 2, 611-617, February 1998
Tulane University School of Medicine and Veterans Affairs Medical
Center, New Orleans, Louisiana
Down-regulation of opiate receptors is demonstrated more easily
in vitro than in vivo. The possible role
of endogenous opiate-modulating peptides in preventing such
down-regulation was investigated by addition of Tyr-W-MIF-1 to an
in vitro preparation, the human neuroblastoma cell line
SH-SY5Y, in which down-regulation of opiate receptors has been
demonstrated previously. Although both morphine and Met-enkephalin
down-regulated mu and delta receptors
after chronic (24 h) exposure in serum-free medium, Tyr-W-MIF-1, at doses of up to 100 µM, did not affect receptor number when
administered alone. This lack of effect could not be attributed to
degradation of the peptide during chronic treatment because
high-performance liquid chromatography showed that 79% of the peptide
remained intact after a 24-h incubation. When coadministered with 3 µM morphine, Tyr-W-MIF-1 dose-dependently attenuated morphine-induced down-regulation of both mu and delta
receptors. Down-regulation of mu receptors by the
selective agonist PL017 was also attenuated by Tyr-W-MIF-1, but
down-regulation of delta receptors by the selective
agonist DPDPE was not. These studies indicate that endogenous opiate
modulators may play a role in opiate tolerance at the level of receptor
down-regulation.